Literature DB >> 10506836

A survey of the sequence-specific interaction of damaging agents with DNA: emphasis on antitumor agents.

V Murray1.   

Abstract

This article reviews the literature concerning the sequence specificity of DNA-damaging agents. DNA-damaging agents are widely used in cancer chemotherapy. It is important to understand fully the determinants of DNA sequence specificity so that more effective DNA-damaging agents can be developed as antitumor drugs. There are five main methods of DNA sequence specificity analysis: cleavage of end-labeled fragments, linear amplification with Taq DNA polymerase, ligation-mediated polymerase chain reaction (PCR), single-strand ligation PCR, and footprinting. The DNA sequence specificity in purified DNA and in intact mammalian cells is reviewed for several classes of DNA-damaging agent. These include agents that form covalent adducts with DNA, free radical generators, topoisomerase inhibitors, intercalators and minor groove binders, enzymes, and electromagnetic radiation. The main sites of adduct formation are at the N-7 of guanine in the major groove of DNA and the N-3 of adenine in the minor groove, whereas free radical generators abstract hydrogen from the deoxyribose sugar and topoisomerase inhibitors cause enzyme-DNA cross-links to form. Several issues involved in the determination of the DNA sequence specificity are discussed. The future directions of the field, with respect to cancer chemotherapy, are also examined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506836     DOI: 10.1016/s0079-6603(08)60727-8

Source DB:  PubMed          Journal:  Prog Nucleic Acid Res Mol Biol        ISSN: 0079-6603


  11 in total

1.  The effect of chromatin structure on cisplatin damage in intact human cells.

Authors:  N P Davies; L C Hardman; V Murray
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

2.  The DNA sequence specificity of bleomycin cleavage in a systematically altered DNA sequence.

Authors:  Shweta D Gautam; Jon K Chen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2017-05-16       Impact factor: 3.358

3.  Zorbamycin has a different DNA sequence selectivity compared with bleomycin and analogues.

Authors:  Jon K Chen; Dong Yang; Ben Shen; Brett A Neilan; Vincent Murray
Journal:  Bioorg Med Chem       Date:  2016-09-30       Impact factor: 3.641

4.  The sequence selectivity of DNA-targeted 9-aminoacridine cisplatin analogues in a telomere-containing DNA sequence.

Authors:  Moumita Paul; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2011-04-05       Impact factor: 3.358

5.  The DNA sequence specificity of bleomycin cleavage in telomeric sequences in human cells.

Authors:  Hanh T Q Nguyen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2012-09-09       Impact factor: 3.358

6.  The genome-wide DNA sequence specificity of the anti-tumour drug bleomycin in human cells.

Authors:  Vincent Murray; Jon K Chen; Mark M Tanaka
Journal:  Mol Biol Rep       Date:  2016-05-17       Impact factor: 2.316

7.  The determination of the DNA sequence specificity of bleomycin-induced abasic sites.

Authors:  Jon K Chen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2016-03-03       Impact factor: 3.358

8.  Characterising the atypical 5'-CG DNA sequence specificity of 9-aminoacridine carboxamide Pt complexes.

Authors:  Hieronimus W Kava; Anne M Galea; Farhana Md Jamil; Yue Feng; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2014-05-15       Impact factor: 3.358

9.  Cisplatin selects short forms of the mitochondrial DNA OriB variant (16184-16193 poly-cytosine tract), which confer resistance to cisplatin.

Authors:  Taku Amo; Naomi Kamimura; Hiromasa Asano; Sadamitsu Asoh; Shigeo Ohta
Journal:  Sci Rep       Date:  2017-04-10       Impact factor: 4.379

10.  Characterisation of the DNA sequence specificity, cellular toxicity and cross-linking properties of novel bispyridine-based dinuclear platinum complexes.

Authors:  Ben W Johnson; Vincent Murray; Mark D Temple
Journal:  BMC Cancer       Date:  2016-05-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.